Recombinant Mouse CSF2, Tag Free
CSF2 was initially characterized as a factor that can support the in vitro colony formation of granulocyte-macrophage progenitors. It is also a growth factor for erythroid, megakaryocyte, and eosinophil progenitors. GM-CSF is produced by a number of different cell types (including T cells, B cells, macrophages, mast cells, endothelial cells, fibroblasts, and adipocytes) in response to cytokine or inflammatory stimuli. On mature hematopoietic cells, GM-CSF is a survival factor for and activates the effector functions of granulocytes, monocytes/macrophages, and eosinophils [1, 2]. GM-CSF promotes a Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity [3-5]. It shows clinical effectiveness in ameliorating chemotherapy-induced neutropenia, and GM-CSF transfected tumor cells are utilized as cancer vaccines [6, 7]. The 22 kDa glycosylated GM-CSF, similar to IL-3 and IL-5, is a cytokine with a core of four bundled alpha -helices [8-10]. Mature mouse GM-CSF shares 49%-54% amino acid sequence identity with canine, feline, human, and porcine GM-CSF and 69% with rat GM-CSF. GM-CSF exerts its biological effects through a heterodimeric receptor complex composed of GM-CSF R alpha /CD116 and the signal transducing common beta chain (CD131) which is also a component of the high-affinity receptors for IL-3 and IL-5 [11, 12]. In addition, GM-CSF binds a naturally occurring soluble form of GM-CSF R alpha [13].
Reference
[1]. Martinez-Moczygemba, et al. (2003) J. Allergy Clin. Immunol. 112:653.
[2]. Barreda, D.R. et al. (2004) Dev. Comp. Immunol. 28:509.
[3]. Eksioglu, E.A. et al. (2007) Exp. Hematol. 35:1163.
[4]. Cao, Y. (2007) J. Clin. Invest. 117:2362.
[5]. Fleetwood, A.J. et al. (2005) Crit. Rev. Immunol. 25:405.
[6]. Heuser, M. et al. (2007) Semin. Hematol. 44:148.
[7]. Hege, K.M. et al. (2006) Int. Rev. Immunol. 25:321.
[8]. Kaushansky, K. et al. (1992) Biochemistry 31:1881.
[9]. Diederichs, K. et al. (1991) Science 254:1779.
[10]. Gough, N.M. et al. (1984) Nature 309:763.
[11]. Onetto-Pothier, N. et al. (1990) Blood 75:59.
[12]. Hayashida, K. et al. (1990) Proc. Natl. Acad. Sci. 87:9655.
[13]. Pelley, J.L. et al. (2007) Exp. Hematol. 35:1483.
|
Accession # |
P01587 |
|
Alternate Names |
Colony-stimulating factor; CSF; CSF2; CSF-2; GMCSF; GM-CSF; Molgramostim; molgramostin |
|
Source |
Human embryonic kidney cell, HEK293-derived mouse CSF2 protein |
|
Protein sequence |
Ala18-Lys141 |
|
M.Wt |
14.1 kDa |
|
Appearance |
Solution protein |
|
Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. - 12 months from date of receipt, -20 to -70°C as supplied. |
|
Concentration |
0. 2 mg/mL |
|
Formulation |
Dissolved in sterile PBS buffer. |
|
Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. This solution can be diluted into other aqueous buffers. |
|
Biological Activity |
The EC50 for this effect is 5-30 pg/mL. Measured in a cell proliferation assay using DA3 mouse myeloma cells. |
|
Shipping Condition |
Shipping with dry ice. |
|
Handling |
Centrifuge the vial prior to opening. |
|
Usage |
For Research Use Only! Not to be used in humans. |
Quality Control & DataSheet
- View current batch:
-
Purity > 95%, determined by SDS-PAGE.
- Datasheet
Endotoxin: <0.010 EU per 1 ug of the protein by the LAL method.